Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Urothelial Cancer × durvalumab × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 14 Carcinoma, Non-Small-Cell Lung 10 Pancreatic Neoplasms 7 Ovarian Neoplasms 7 Lung Neoplasms 7 Head and Neck Neoplasms 6 Colorectal Neoplasms 6 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Urinary Bladder Neoplasms 4 Neoplasm Metastasis 4 Carcinoma, Hepatocellular 4 Biliary Tract Neoplasms 4 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Neoplasms 3 Kidney Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Squamous Cell 3 Carcinoma, Renal Cell 3 Carcinoma 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, T-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2

Interventions

niraparib 1 durvalumab 1 cabozantinib 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02891161 2024-11-27

DUART

Big Ten Cancer Research Consortium

Phase 1/2 Terminated

26 enrolled 20 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡